Search | Clinical Trials Finder

Conditions: Short Bowel Syndrome
Interventions: Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome; Device
Lead sponsor: Eclipse Regenesis, Inc.; Other
Eligibility: 3 Months to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 2 more

Conditions: Lymphedema, Lymphedema, Breast Cancer
Interventions: Axillary lymphadenetomy alone, axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA), axillary lymphadenectomy with soft tissue reinforcement; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Short Bowel Syndrome
Interventions: HM15912 Active, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Cleveland, Ohio

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride; Procedure · Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 4
States / cities: Baltimore, Maryland • Bozeman, Montana • Seattle, Washington + 1 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Leukemia, Acute, MDS
Interventions: Bone Marrow or Peripheral Blood Graft (BMT), Cancer-directed Therapy or Best Supportive Care, Frailty Assessment; Procedure · Other · Diagnostic Test
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: CTX340, Placebo; Drug
Lead sponsor: CRISPR Therapeutics AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Port Orange, Florida

Conditions: Overweight or Obesity
Interventions: Active Control, JITAI Combined with psychological intervention; Behavioral
Lead sponsor: ORI Community and Evaluation Services; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Springfield, Oregon

Conditions: Acute DVT of Lower Extremity, Acute Limb Ischemia, Arterial Embolism and Thrombosis, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg, LE ALI, Lower Extremity Acute Limb Ischemia, Peripheral Arterial Disease, Thrombus in the Peripheral Venous Vasculature, Venous Embolism of Lower Extremities (Diagnosis)
Interventions: Liberant Thrombectomy System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Naples, Florida • New York, New York + 1 more

Conditions: Obesity
Interventions: Community Asset Mapping (CAM), Community-Engaged Health Coaching and Navigation, Health Literacy and Culturally Tailored Materials, Obesity Toolkit for Primary Care Providers, Primary Care Provider Training, Self-Monitoring and Remote Patient Monitoring of weight and physical activity; Other · Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Avondale, Louisiana • Bastrop, Louisiana • Baton Rouge, Louisiana + 15 more

Conditions: Sarcoma,Soft Tissue
Interventions: Eribulin, INT230-6, Pazopanib, Trabectedin; Drug
Lead sponsor: Intensity Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 5 more

Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Anti-STEAP1 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Enzalutamide, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography; Biological · Procedure · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Opioid Use Disorder, Sleep Disturbance
Interventions: Actigraphy, DLMO, Ecological Momentary Assessments, Melatonin Suppression Test, Multiple Sleep Latency Test, Polysomnography, Post-Illumination Pupillary Response (PIPR); Device · Other · Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hand Weakness, Stroke
Interventions: NoNo, occupational therapy - self directed; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ulcerative Colitis Acute
Interventions: Cyclosporine Injection (IV), Cyclosporine Oral Product, Intravenous Methylprednisolone, Prednisone Oral Product, Upadacitinib Extended Release Oral Tablet; Drug
Lead sponsor: Berinstein, Jeffrey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Anorexia Nervosa
Interventions: Positive Affect Treatment for Anorexia Nervosa (PAT-AN):, Psychoeducational and Behavioral Therapy (PBT); Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Behavior, Behavior and Behavior Mechanisms, Behavior, Child, Child Development, Cognition, Cognition Disorder, Cognitive Abnormality, Cognitive Change, Cognitive Deficits, Mild, Cognitive Delay, Mild, Cognitive Developmental Delay, Cognitive Dysfunction, Cognitive Impairment, Mild, Cognitive Orientation, Decision Making, Developmental Disability, Dyscalculia, Dyscalculia, Acquired, Dyscalculia, Primary, Individuality, Learning Curve, Learning Disabilities, Learning Disabled, Math Learning Disability, Mathematics Disorder, Neuronal Plasticity, Neuroscience, Specific Learning Disorder, With Impairment in Mathematics
Interventions: Interventions in Mathematics and Cognitive Skills - Active Comparator, Interventions in Mathematics and Cognitive Skills - Experimental; Other
Lead sponsor: Stanford University; Other
Eligibility: 6 Years to 12 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Schizophrenia
Interventions: active intermittent Theta Burst Stimulation (iTBS), sham intermittent Theta Burst Stimulation (iTBS); Device
Lead sponsor: Fabio Ferrarelli; Other
Eligibility: 18 Years to 40 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Barrett Esophagus, Esophageal Adenocarcinoma
Interventions: Biospecimen Collection, Esophageal Biopsy, Esophagogastroduodenoscopy, Liver Ultrasonographic Elastography, Obeticholic Acid, Placebo Administration, Questionnaire Administration; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Kansas City, Kansas • Ann Arbor, Michigan • St Louis, Missouri + 2 more

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Biospecimen Collection, Bronchoscopy with Bronchoalveolar Lavage, Chemoradiotherapy, Computed Tomography, Diagnostic Laboratory Biomarker Analysis, Immune Checkpoint Inhibitor, Nasal Wash and Collection, Quality-of-Life Assessment, Questionnaire Administration, Spirometry; Procedure · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain, Major Depressive Disorder
Interventions: Active rTMS/Active iTBS, Active rTMS/Active iTBS DFPLC/Sham Pain M1; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Carcinoma, Malignant Respiratory Tract Neoplasm, Metastatic Malignant Neoplasm in the Lung
Interventions: Biphasic Positive Airway Pressure, Computed Tomography, Continuous Positive Airway Pressure, Deep Inspiration Breath Hold, Radiation Therapy Treatment Planning and Simulation, Stereotactic Body Radiation Therapy; Device · Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Carcinoma
Interventions: Biospecimen Collection, Mammography, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 25 Years to 80 Years · Female only
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Radiation Therapy
Interventions: MRI or CT; Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 937 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

Testing Just-in-Time Adaptive Interventions (JITAIs) to Prevent Goal Disengagement in Response to Weight Regain

Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

Collaborative Multi-level Obesity Intervention Engaging Communities Trial

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

Self-Administered Gaming and Exercise at Home (SAGEH)

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

Neuroscience-informed Treatment to Remotely Target Reward Mechanisms in Post-acute Anorexia Nervosa

Interventions in Mathematics and Cognitive Skills

Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

Obeticholic Acid for Prevention in Barrett's Esophagus

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

Pain and Major Depressive Disorder

Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer

Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study

Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment